BioCentury
ARTICLE | Clinical News

More Phase III adefovir HBV data

November 9, 2001 8:00 AM UTC

Gilead (GILD) said interim 16-week data from an ongoing Phase III trial (Study 461) of its adefovir dipivoxil to treat lamivudine-resistant chronic hepatitis B virus (HBV) infection and compensated li...